CGS-authored
A review of California's stem cell research funding agency proposed changes to the agency's governing structure and commercial goals while praising its results so far.
The 124-page report from the Institute of Medicine recycles many conflict of interest and intellectual property concerns that have dogged the San Francisco-based California Institute for Regenerative Medicine, or CIRM, since California voters in 2004 approved $3 billion in state-backed bonds to fund stem cell research over 10 years.
The IOM committee, a panel of scientists and academics led by former Princeton University President Harold Shapiro and Terry Magnuson, vice dean for research in the medical school of the University of North Carolina at Chapel Hill, recommended that:
• CIRM's oversight board get out of day-to-day operations;
• The 29-person board's composition be changed to include more members without perceived conflicts of interest and that the agency revise its conflict of interest definitions to include non-financial interests;
• CIRM continue to focus on advancing stem cell technologies that underpin the success or failure of a disease treatment, rather than getting therapies into clinical trials;
•...
The 124-page report from the Institute of Medicine recycles many conflict of interest and intellectual property concerns that have dogged the San Francisco-based California Institute for Regenerative Medicine, or CIRM, since California voters in 2004 approved $3 billion in state-backed bonds to fund stem cell research over 10 years.
The IOM committee, a panel of scientists and academics led by former Princeton University President Harold Shapiro and Terry Magnuson, vice dean for research in the medical school of the University of North Carolina at Chapel Hill, recommended that:
• CIRM's oversight board get out of day-to-day operations;
• The 29-person board's composition be changed to include more members without perceived conflicts of interest and that the agency revise its conflict of interest definitions to include non-financial interests;
• CIRM continue to focus on advancing stem cell technologies that underpin the success or failure of a disease treatment, rather than getting therapies into clinical trials;
•...